3-cyano-2-(4-methylphenoxy)pyridine | 82523-98-6

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: 3-cyano-2-(4-methylphenoxy)pyridine
• 英文别名: 2-(4-Methylphenoxy)pyridine-3-carbonitrile
• CAS: 82523-98-6
• 化学式: C₁₃H₁₀N₂O
• mdl: MFCD09935936
• 分子量: 210.235
• InChiKey: VKXGDTUOYQBTJM-UHFFFAOYSA-N

物化性质

• 熔点：
  106-107 °C(Solv: ethanol (64-17-5))
• 沸点：
  341.8±32.0 °C(Predicted)
• 密度：
  1.19±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.8
• 重原子数：
  16
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.076
• 拓扑面积：
  45.9
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  3-cyano-2-(4-methylphenoxy)pyridine 在 硫酸 作用下， 以 乙醚 、 溶剂黄146 为溶剂， 反应 12.0h， 生成 6-Methyl-10-phenyl-10H-9-oxa-1-aza-anthracen-10-ol
  参考文献：
  名称：

  Synthesis and acid-base transformations of 8-substituted 10-phenyl-10-hydroxy-10H- pyrido [2,3-b ]chromenes

  摘要：

  DOI：

  10.1007/bf00526076
• 作为产物：
  描述：

  2-氯-3-氰基吡啶 、 sodium 4-methylphenoxide 以 various solvent(s) 为溶剂， 反应 0.5h， 以77%的产率得到3-cyano-2-(4-methylphenoxy)pyridine
  参考文献：
  名称：

  Synthesis and acid-base transformations of 8-substituted 10-phenyl-10-hydroxy-10H- pyrido [2,3-b ]chromenes

  摘要：

  DOI：

  10.1007/bf00526076

文献信息

• Etherification of Functionalized Phenols with Chloroheteroarenes at Low Palladium Loading: Theoretical Assessment of the Role of Triphosphane Ligands in CO Reductive Elimination
  作者：Mélanie Platon、Luchao Cui、Sophal Mom、Philippe Richard、Mark Saeys、Jean-Cyrille Hierso

  DOI：10.1002/adsc.201100481

  日期：2011.12

  tolerates very important functions in various positions, such as cyano, methoxy, amino, and fluoro groups, which is useful to synthesize bioactive molecules. DFT studies furthermore demonstrate that triphosphane ligands open up various new pathways for the CO reductive elimination involving the third phosphane group. In particular, the rate for one of these new pathways is calculated to be about 1000 times

  本研究强调了具有可控构象的稳健三齿二茂铁基膦烷在CO键形成反应中作为催化助剂的潜力。空气稳定的钯三膦体系通过使用低至0.2 mol％的催化剂，对于选择性杂芳基醚合成非常有效。这些发现代表了功能性酚，富电子，贫电子和对位，间位或邻位的酚在经济上有吸引力的清洁醚化-被取代的底物，其具有杂芳基氯化物，包括吡啶，羟基化吡啶，嘧啶和噻唑。醚化耐受各种位置的非常重要的功能，例如氰基，甲氧基，氨基和氟基团，这些功能可用于合成生物活性分子。DFT研究进一步表明，三膦配体为涉及第三膦基团的CO还原消除开辟了各种新途径。特别地，这些新途径之一的速率经计算比从具有相似二茂铁基配体但在底部Cp环上没有膦基的复合物进行还原消除的速率快约1000倍。计算了第三膦基与钯（II）中心的配位，以稳定该新途径中的过渡态，
• 1,4 disubstituted 3 cyano pyridone derivatives and their use as positive allosteric modulators of mGluR2 receptors
  申请人：Ortho-McNeil-Janssen Pharmaceuticals, Inc.

  公开号：EP2426125A1

  公开（公告）日：2012-03-07

  The present invention relates to novel compounds, in particular novel pyridinone derivatives according to Formula (I) wherein all radicals are defined in the application and claims. The compounds according to the invention are positive allosteric modulators of metabotropic receptors - subtype 2 ("mGluR2") which are useful for the treatment or prevention of neurological and psychiatric disorders associated with glutamate dysfunction and diseases in which the mGluR2 subtype of metabotropic receptors is involved. In particular, such diseases are central nervous system disorders selected from the group of anxiety, schizophrenia, migraine, depression, and epilepsy. The invention is also directed to pharmaceutical compositions and processes to prepare such compounds and compositions, as well as to the use of such compounds for the prevention and treatment of such diseases in which mGluR2 is involved.

  本发明涉及新型化合物，特别是符合式 (I) 的新型吡啶酮衍生物 其中所有基团在申请和权利要求中均有定义。根据本发明的化合物是代谢受体-亚型 2（"mGluR2"）的正异位调节剂，可用于治疗或预防与谷氨酸功能障碍相关的神经和精神疾病以及涉及代谢受体的 mGluR2 亚型的疾病。特别是，这类疾病是选自焦虑症、精神分裂症、偏头痛、抑郁症和癫痫组的中枢神经系统疾病。本发明还涉及药物组合物和制备此类化合物及组合物的工艺，以及使用此类化合物预防和治疗涉及 mGluR2 的此类疾病。
• PETRICHENKO, V. M.;KONSHIN, M. E., XIMIYA GETEROTSIKL. SOEDIN., 1982, N 5, 614-616
  作者：PETRICHENKO, V. M.、KONSHIN, M. E.

  DOI：——

  日期：——
• PETRICHENKO, V. M.;KONSHIN, M. E.
  作者：PETRICHENKO, V. M.、KONSHIN, M. E.

  DOI：——

  日期：——
• 1, 4-Disubstituted 3-Cyano-Pyridone Derivatives and Their Use As Positive Allosteric Modulators of MGLUR2-Receptors
  申请人：JANSSEN PHARMACEUTICALS, INC.

  公开号：US20140315903A1

  公开（公告）日：2014-10-23

  The present invention relates to novel compounds, in particular novel pyridinone derivatives according to Formula (I) wherein all radicals are defined in the application and claims. The compounds according to the invention are positive allosteric modulators of metabotropic receptors—subtype 2 (“mGluR2”) which are useful for the treatment or prevention of neurological and psychiatric disorders associated with glutamate dysfunction and diseases in which the mGluR2 subtype of metabotropic receptors is involved. In particular, such diseases are central nervous system disorders selected from the group of anxiety, schizophrenia, migraine, depression, and epilepsy. The invention is also directed to pharmaceutical compositions and processes to prepare such compounds and compositions, as well as to the use of such compounds for the prevention and treatment of such diseases in which mGluR2 is involved.